Erythromycin as a Prokinetic Agent in Pediatrics

Introduction to Prokinetic Use

The American Academy of Pediatrics recommends against the routine use of any prokinetic agent, including erythromycin, for the treatment of gastroesophageal reflux disease in infants or children due to lack of evidence of benefit and significant risk of adverse effects 1
Each prokinetic agent works through a different mechanism, but all have demonstrated significant adverse effects that outweigh their potential benefits 1

The infusion should be administered slowly over ≥60 minutes to reduce gastrointestinal adverse effects, as recommended by the Centers for Disease Control and Prevention 1, 2
The American Academy of Pediatrics suggests that when erythromycin is used, it should be replaced with oral therapy as soon as clinically possible 3

Erythromycin is associated with a risk of hypertrophic pyloric stenosis in neonates under 1 month, and should be avoided in this age group, according to the American Academy of Pediatrics 1, 4
The Centers for Disease Control and Prevention warn that erythromycin can cause significant gastrointestinal side effects, including nausea, vomiting, abdominal pain, and diarrhea 4
The use of erythromycin can lead to hepatotoxicity, although this is rare (2% of reported cases), as noted by the Centers for Disease Control and Prevention 3
The Centers for Disease Control and Prevention also caution that erythromycin can cause potentially fatal episodes of ventricular tachycardia associated with QTc interval prolongation, especially in neonates 3

The American Academy of Pediatrics notes that metoclopramide has a higher risk of adverse events compared to erythromycin (OR 1.21, 95% CI 1.03-1.43) 1
Metoclopramide has a black box warning for extrapyramidal effects, with adverse effects reported in 11-34% of patients, including somnolence, restlessness, and extrapyramidal reactions, as warned by the American Academy of Pediatrics 1

Azithromycin is preferred over erythromycin due to its better safety profile, especially in young infants, with significantly fewer gastrointestinal side effects, as recommended by the American Academy of Pediatrics 4
For respiratory infections, azithromycin has a dose of 10 mg/kg (maximum 500 mg) on day 1, followed by 5 mg/kg (maximum 250 mg) daily for days 2-5, as suggested by the Centers for Disease Control and Prevention 5

The American Academy of Pediatrics advises against using erythromycin as first-line treatment for gastroesophageal reflux disease, as there is no sufficient evidence for its routine use 1
Erythromycin should not be used in neonates under 1 month due to the risk of hypertrophic pyloric stenosis, as warned by the American Academy of Pediatrics 4
The Centers for Disease Control and Prevention caution against administering erythromycin with antacids containing aluminum or magnesium, as they reduce absorption 3
Erythromycin should not be combined with astemizole, cisapride, pimozide, or terfenadine due to the risk of severe cardiac arrhythmias, as warned by the Centers for Disease Control and Prevention 4